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Abstract The cyclo-octapdepsipeptide anthelmintic
emodepside exerts a profound paralysis on parasitic and
free-living nematodes. The neuromuscular junction is a
significant determinant of this effect. Pharmacological and
electrophysiological analyses in the parasitic nematode
Ascaris suum have resolved that emodepside elicits a
hyperpolarisation of body wall muscle, which is dependent
on extracellular calcium and the efflux of potassium ions.
The molecular basis for emodepside’s action has been
investigated in forward genetic screens in the free-living
nematode Caenorhabditis elegans. Two screens for emo-
depside resistance, totalling 20,000 genomes, identified
several mutants of slo-1, which encodes a calcium-acti-
vated potassium channel homologous to mammalian BK
channels. Slo-1 null mutants are more than 1000-fold less
sensitive to emodepside than wild-type C. elegans and
tissue-specific expression studies show emodepside acts on
SLO-1 in neurons regulating feeding and motility as
well as acting on SLO-1 in body wall muscle. These
genetic data, combined with physiological measurements
in C. elegans and the earlier physiological analyses on
A. suum, define a pivotal role for SLO-1 in the mode of
action of emodepside. Additional signalling pathways have
emerged as determinants of emodepside’s mode of action
through biochemical and hypothesis-driven approaches.
Mutant analyses of these pathways suggest a modulatory
role for each of them in emodepside’s mode of action;
however, they impart much more modest changes in the
sensitivity to emodepside than mutations in slo-1. Taken
together these studies identify SLO-1 as the major deter-
minant of emodepside’s anthelmintic activity. Structural
information on the BK channels has advanced significantly
in the last 2 years. Therefore, we rationalise this possibility
by suggesting a model that speculates on the nature of the
emodepside pharmacophore within the calcium-activated
potassium channels.
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Receptors and effectors for emodepside
Emodepside is a semi-synthetic derivative of the cyclo-
octadepsipeptide PF1022A, a secondary metabolite of the
fungus Rosellinia spp. PF1022. It is effective against a
wide-range of parasitic nematodes and has anthelmintic-
resistance breaking properties suggesting a novel mode of
action, for review see (Krucken et al. 2012). A key aspect
of its efficacy is its ability to interfere with neuromuscular
transmission in parasitic nematodes, an effect that was
shown to be both calcium- and potassium dependent
(Willson et al. 2003). It also inhibits neuromuscular func-
tion in the free-living nematode C. elegans, disrupting
feeding, egg-laying and motility (Bull et al. 2007). The
inhibition of motility leads to complete paralysis and
is consistent with dysfunction at the neuromuscular junc-
tion. Observation of the flaccid paralysis triggered by
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emodepside suggests that it inhibits muscle contraction.
This could arise through a direct effect on muscle and/or an
indirect effect through the excitatory neural network that
drives muscle contraction. Regardless of the locus of the
effector for paralysis in C. elegans, this behavioural effect
provides a very tractable assay for forward and reverse
genetics and thus it has been used to identify the molecular
determinants of emodepside’s anthelmintic action.
The ability of emodepside to break the resistance of
parasitic nematodes to other anthelmintic agents (von
Samson-Himmelstjerna et al. 2005) had already indicated
that it exerts its actions through a novel target(s). This
important prediction was confirmed when it was shown that
SLO-1, a calcium-activated potassium channel, is required
for the effect of emodepside in C. elegans (Guest et al.
2007), and this observation was later confirmed for para-
sitic nematodes (Welz et al. 2011). SLO-1 potassium
channels belong to a family of high-conductance ion
channels, designated BK for ‘big K? conductance’, that are
activated by changes in membrane voltage, that is, depo-
larisation and by increased cytoplasmic calcium ion con-
centration. This dual regulation confers on them a key role
in neuronal, muscle and endocrine function throughout the
animal phyla (Salkoff et al. 2006). In C. elegans, slo-1 is
expressed in both the nervous system and body wall muscle
and the slo-1 null mutant has pharyngeal, motility and egg-
laying phenotypes, indicating it has a role in regulating
these behaviours (Bull et al. 2007; Holden-Dye et al. 2007).
This provides a locus for the disruption of these behaviours
by emodepside. Experiments in which wild-type slo-1 was
re-introduced into the slo-1 null mutant C. elegans in a
tissue-specific manner have provided evidence that the
emodepside-induced paralysis requires a contribution from
neuronal and body wall muscle to exert full inhibition of
locomotion (Guest et al. 2007). This same experimental
approach was used to introduce the mammalian homologue
of slo-1, kcnma1, into the slo-1 null C. elegans mutant.
Expression of the human channel rescued slo-1 deficient
behaviours in a similar fashion to expression of the native
C. elegans channel slo-1 (Crisford et al. 2011), thus sug-
gesting that it is possible to functionally reconstitute the
mammalian channel in C. elegans. However, when worms
expressing either slo-1 or kcnma1 were compared with
respect to the efficacy of emodepside to inhibit motility or
pharyngeal activity, those expressing the nematode channel
were at least 10-fold more sensitive to emodepside than
worms expressing the human channel. This observation has
been reinforced by investigations in which the same
approach was used to compare the effect of emodepside on
SLO-1 channels from several parasitic nematodes (Welz
et al. 2011). These experiments confirmed the sensitivity of
the parasitic nematode slo-1 to emodepside. This suggests
that structural or conformational differences between the
calcium-activated potassium channel isoforms may con-
tribute to emodepside’s selective action on the parasite
(Crisford et al. 2011). Comparisons of its efficacy at dif-
ferent isoforms of the calcium-activated potassium channel
might provide important clues to its molecular target within
the calcium-activated potassium channels. Recently, it has
been reported that there are at least twelve splice variants
of C. elegans slo-1 (Glauser et al. 2011) and that the
presence of different exons impacts on the activation of the
channel and its sensitivity to intracellular calcium ions
(Johnson et al. 2011). Thus, another strand to consider is
the possibility that differences in alternative splicing of slo-1
between species might influence emodepside sensitivity.
An important feature of the in vivo pharmacological
experiments described above is that they provide a direct
quantitative comparison of the susceptibility of wild-type,
mutant and transgenic C. elegans to emodepside. The
results from these studies can further inform on putative
receptors and pathways that might contribute to emodep-
side’s effect. Predominant among these candidates is the
phylogenetically conserved latrophilin receptor. Latrophilin
was identified as a candidate receptor for cyclo-octadepsi-
peptides by expression cloning from Haemonchus contortus
(Saeger et al. 2001). It is a Class B G-protein-coupled
receptor, so-called, because it binds the black widow spider
toxin, latrotoxin (Lelianova et al. 1997). The mammalian
version of this receptor is implicated in regulating synaptic
function (Silva et al. 2011). Latrophilins have been identi-
fied in parasitic nematodes and these present another
interesting target with respect to emodepside (Kru¨ger et al.
2009). The significance of latrophilin in the mode of action
of emodepside has been investigated by gene knockdown
through RNAi, and gene knockouts in C. elegans (Willson
et al. 2004). In a latrophilin null mutant (carrying deletions
in both latrophilin genes, lat-1 and lat-2), there is a 20-fold
reduction in the sensitivity of the pharyngeal system to
emodepside. The role for latrophilin appears reinforced by
the comparative analysis of emodepside sensitivity in
worms that are genetically deficient in key downstream
pathways that might be activated by latrophilin receptors
(Willson et al. 2004; Amliwala 2005; Bull 2007). Mutations
in these genes confer up to a 50-fold reduction in sensitivity
to the effects of emodepside on either C. elegans motility or
pharyngeal activity (Table 1). These pathways regulate
calcium signalling and membrane potential, two essential
factors in slo-1 function, which might provide the basis for
an interaction of latrophilin and SLO-1 in emodepside’s
effects. These studies are of interest as they may inform the
development of combined therapies that incorporate addi-
tional drugs with emodepside to optimise the anthelmintic
action in some target species of parasitic nematode. Indeed,
some C. elegans mutations confer an increase in emo-
depside sensitivity, suggesting that antagonists of these
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pathways may merit further investigation as a means of
providing synergy with the anthelmintic effects of emo-
depside (Willson et al. 2004; Amliwala 2005). The potential
for modulation of SLO-1 core activity is consistent with
modest but clear pharmacological regulation of emodep-
side-dependent activation of calcium-activated potassium
channels in A. suum muscle (Buxton et al. 2011).
Whilst several pathways might impact on emodepside
sensitivity, the fact that the C. elegans reverse genetic
screen thus far only yielded slo-1 mutants indicates that
this is likely to be the major locus of action. This is also
likely to be the case in parasitic nematodes as penitrem A, a
selective calcium-activated potassium channel antagonist,
potently blocks the paralytic effect of emodepside on
Ancylostoma caninum (Welz et al. 2011). These observa-
tions indicate that SLO-1 is the major mediator of the
anthelmintic action in parasites as well as C. elegans (Welz
et al. 2011). Nonetheless, the relative role of slo-1 and
latrophilin in the efficacy of emodepside against different
species of nematodes might be an avenue to explore fur-
ther. In this regard, it is interesting to note that there is a
precedent for a difference in anthelmintic action between
species of nematode as ivermectin inhibits feeding in
A. suum and C. elegans (Brownlee et al. 1997; Pemberton
et al. 2001) through an action on glutamate-gated chloride
channels; however, ivermectin does not affect the pharynx
of Ascaridia galli (Holden-Dye and Walker 2006).
Clues to the mode of action based on the time-course
of action of emodepside
Emodepside is a highly lipophilic compound with a logP
value of 4.9 (octanol/water: http://sitem.herts.ac.uk/aeru/
vsdb/Reports/1838.htm). With this in mind, it is interesting
to note that the effect of emodepside on neuromuscular
function, whether observed by behavioural analysis or by
electrophysiological recordings, typically has a relatively
long time-course for the development of the maximal
effect. This has clearly been demonstrated for the effect on
the body wall muscle of A. suum (Willson et al. 2003;
Buxton et al. 2011). Also, for C. elegans, the indication is
that emodepside has a slow time-course of action. For
example, the motility of intact adult C. elegans immersed
in saline containing emodepside is inhibited after 10 min
but the maximum effect takes an hour to develop (Fig. 1a).
The interpretation of this observation is confounded by the
fact that in part this may be explained by the time taken for
emodepside to gain access to the interior of the worm,
either by ingestion or by crossing the cuticle. Nonetheless
the slowly accumulating effect is consistent with the idea
that once emodepside is distributed in the worm, it must
then accumulate at the target site in order to elicit its effect.
In a cut pharyngeal preparation from C. elegans, used to
measure the effect on pharyngeal pumping, the cuticle no
longer presents a barrier, and this can provide a clearer
insight into the time-course of the effect. The inhibition of
pharyngeal pumping by emodepside, either basal (Fig. 1b)
(Crisford et al. 2011) or stimulated by 5-HT (Willson et al.
2004), takes minutes to appear whilst the effects of other
bioactive hydrophilic agents, for example, either octopa-
mine or the neuropeptide AF1 occurs rapidly, within sec-
onds (Rogers et al. 2001). A plausible explanation for these
observations on the time-course of the action of emodep-
side is that it reflects its hydrophobicity and as it partitions
into the membrane, it gains access to a drug recognition
site that lies in the transmembrane domains of the protein.
Such a recognition site may well be within or between the
Table 1 A summary of genes that regulate emodepside sensitivity in the nematode C. elegans
Gene Pharynx Locomotion Signalling cascade
slo-1 ;1000 fold ;1000 fold Ion channel
lat1/lat2 ;10-fold No change GPCR
goa-1 :10-fold :50 fold G-protein
egl-30 (lof) ;50-fold ;3 fold G-protein
egl-30 (gof) :20-fold :20 fold G-protein
egl-8 ;14-fold ;10 fold Phospholipase C
unc-13 ;40-fold – Transmitter release
unc-10 No change – Transmitter release
snb-1 ;30-fold – Transmitter release
unc-31 ;5-fold – Transmitter release
The sensitivity to emodepside of the C. elegans mutants listed was compared in parallel assays with the sensitivity of wild-type animals and the
relative sensitivity of the mutant compared to wild-type expressed as a fold reduction (;) or a fold increase (:). ‘lof’ indicates a loss of function
mutant and ‘gof’ indicates a gain-of-function mutant. The left-hand column indicates the mutants that were assayed. The effect of emodepside
was determined in a pharyngeal assay in which extracellular electrophysiological recordings were made from the pharynx (Willson 2003;
Willson et al. 2004; Bull 2007) and on locomotion in which the effect of emodepside on the frequency of locomotion on agar medium was
determined (Amliwala 2005)
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helices that comprise the channel or at the protein/lipid
interface within the bilayer. The nanomolar concentration
in solution at which emodepside exerts behavioural inhi-
bition of C. elegans suggests that it exerts its effects when
the emodepside/lipid ratio (i.e. mole/mole ratio) is low.
This supports the notion that a specific emodepside/protein
or emodepside/protein/lipid interaction underpins its mode
of action. A similar train of thought suggests that at
micromolar concentrations of emodepside, a concentration
that is difficult to keep in aqueous solution, emodepside
would appear in the membrane at a 1:1 emodepside/lipid
ratio where one might expect to see additional membrane
perturbant effects. Indeed, this expectation is realised by
the report that the parent compound of emodepside,
PF1022A, has ionophore properties and directly confers
ion channel activity on membranes, although this appears
unrelated to its anthelmintic action (Geßner et al. 1996;
Dornetshuber et al. 2009).
Although the biophysical nature of emodepside strongly
supports a membrane-associated binding site, this does not
a priori predict a slow time-course on the biological action.
It is informative to consider that local anaesthetics that
have to partition into the membrane to elicit their biolog-
ical effect may exhibit a slow time-course that is dictated
by their rate of entry into the membrane, and this may also
be the situation for emodepside. Alternatively the rate of
onset of the biological effect of emodepside could reflect
its rate of access and binding to its target site within the
membrane. An additional possibility that would influence
the time-course of the biological effect is that emodepside
may preferentially bind to a specific conformation of the
SLO-1 channel, that is, it may exhibit state-dependent
binding to its target. There are a number of precedents for
this latter interaction in which drugs bind within the
membrane to open or allosterically modified ion channel or
transporter conformations, for example, ouabain (Qiu et al.
2005; Sandtner et al. 2011) and thapsigargin (Winther et al.
2010). Whatever the precise interaction of emodepside
with the calcium-activated potassium channel, it is clear
from the various experimental observations to date that its
biological effect is exerted over a prolonged time-course
and understanding the mechanistic underpinning of this
phenomenon will provide further insight into its mode of
action.
Does emodepside interact directly with SLO-1?
The profound drug resistance imparted by the slo-1 loss of
function mutations in C. elegans (Guest et al. 2007)
strongly suggests that SLO-1 harbours the emodepside
binding site. Furthermore, genetic analysis and physiolog-
ical observations are consistent with the idea that emo-
depside acts to open the channel. This proposal also
marries well with electrophysiological recordings of the
effect of emodepside on A. suum muscle (Willson et al.
2003; Buxton et al. 2011) which are consistent with
opening of a calcium-activated potassium conductance.
There are at least two alternative mechanisms through
which emodepside could exert this action. It could influ-
ence the dependence of the SLO-1 channel on membrane
potential (depolarisation) and/or its regulation by intracel-
lular calcium ions (Salkoff et al. 2006). Furthermore, the
molecular organisation of SLO-1 channels and their
Fig. 1 Examples of the time-course of the effect of emodepside on
C. elegans motility and feeding. a The time-course of the inhibitory
effect of emodepside on motility in liquid: control n = 10, emodep-
side n = 27, mean ± SE mean. The thrashing rate in each treatment
group was measured at time 0 and then followed for a further 60 min
at 10 min intervals. The thrashing rate at each time-point is expressed
as a percentage of the initial thrashing rate at time 0. The vehicle was
0.1 % ethanol and the thrashing rate of this control group did not alter
significantly over the time-course of the experiment (Amliwala 2005).
b An example of the time-course of the effect of emodepside on
pharyngeal activity in a cut head preparation. The recordings are
extracellular electrophysiological recordings taken from the pharyn-
geal muscle. Each vertical deflection records a pharyngeal muscle
contraction–relaxation cycle or pump. The bar indicates the duration
of application of emodepside. Emodepside acts on SLO-1 in the
pharyngeal circuit to inhibit pumping (Guest et al. 2007; Dillon et al.
2009). Note this experiment was performed in the absence of any
5-HT (which may be used to provide an excitation against which
inhibition can be measured) and that in the absence of 5-HT the basal
pumping rate in the cut head preparation is very slow. This recording
illustrates the slow time to onset of the emodepside inhibition but the
rapid manner in which pumping is turned off following this latency of
onset. This can be explained by considering that at low rates of
pumping, when the excitatory neuronal input to the pharynx is
minimal, the inhibitory effect of emodepside is sufficient to turn
pumping off completely. The data are taken from (Bull 2007)
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mammalian orthologues suggest that in addition to the core
tetramer of SLO-1 a subunits that form the ion channel,
there are a number of associated b subunits and scaffolding
proteins that support function (Salkoff et al. 2006) through
which emodepside could also exert its effect. Recently such
an accessory subunit, designated BKIP, has been identified
in C. elegans (Chen et al. 2010). Thus, nematode SLO-1
channels may co-assemble with accessory subunits in a
similar fashion to the mammalian channels, and this may
impart drug sensitivity. Nonetheless, experiments in which
recombinant slo-1 is heterologously expressed demonstrate
that the core SLO-1 a-subunit tetramer can reconstitute a
calcium- and voltage-activated channel that is emodepside
sensitive. Preliminary data from this work, reported at
the Ion Channel Symposium, Philadelphia 2011 (Crisford,
Holden-Dye, O’Kelly, Harder, Welz, O’Connor and Walker),
showed that emodepside facilitates activation of SLO-1
channels heterologously expressed in HEK293 cells. This
is consistent with an earlier study in which the sensitivity
of C. elegans pharynx to emodepside in a slo-1 null mutant
was conferred by ectopic over-expression of slo-1 (Crisford
et al. 2011) (Fig. 2). Taken together these data suggest that
SLO-1 can impart a molecular target with sensitivity to
emodepside. That this is achieved via expression of the a
subunit suggests that this moiety involving the tetrameric
assembly of the SLO-1 channel harbours the likely target
site, which will be in the membrane or at an interface
between the membrane and the extracellular or intracellular
compartment.
As the likely action of emodepside is to facilitate
channel function, one might predict that it interacts allos-
terically to modulate the channel by binding to voltage or
calcium sensing domains or the gating mechanisms that
control SLO-1 channel opening. The location of the func-
tional domains in the BK channel has recently been
reviewed (Latorre et al. 2010) (Fig. 3). Interestingly,
regions within these domains, especially the calcium sensor
or ‘calcium bowl’ (Crisford et al. 2011), are among the
most conserved among the mammalian and nematode
SLO-1 channels. The binding sites for a number of toxins
that interact with BK channels have been mapped onto this
overall structure. The interactions of charybdotoxin, ibe-
riotoxin and tetraethylammonium (TEA) are determined
by the extracellular face of the pore forming domains of
the channel, S5 and S6 (MacKinnon and Miller 1989;
Mullmann et al. 1999). However, the hydrophobicity of
emodepside and its prolonged time-course of action sug-
gest that rather than act at a similar extracellular facing site
as these aforementioned toxins, it may access a binding site
on the channel within the lipid membrane. The membrane
harbours the domain that confers voltage sensing capability
on the ion channel protein. This comprises four positively
Fig. 2 Activation of SLO-1 by emodepside. A cartoon to illustrate
data from Crisford et al. (2011) which showed that ectopic expression
of slo-1 in C. elegans pharynx conferred sensitivity to emodepside in
an otherwise emodepside resistant strain, slo-1 (js379), consistent
with the proposal that emodepside interacts with the channel. a Wild-
type C. elegans express slo-1 in pharyngeal neurones and not muscle
(Chiang et al. 2006). Application of emodepside inhibits pharyngeal
activity (recorded by an electropharyngeogram, EPG) by interfering
with signalling in the pharyngeal circuit in a slo-1 dependent manner
(Guest et al. 2007). b The slo-1 null mutant has an altered pattern of
pharyngeal activity that consists of bursts of pumps occurring
together, represented by the cartoon of the EPG. This reflects the
role of slo-1 in patterning the activity in the neural circuit that drives
feeding behaviour (Dillon et al. 2009). However, the slo-1 mutant is
completely resistant to the inhibitory effects of emodepside, consis-
tent with its pivotal in the mode of drug action (Dillon et al. 2009;
Crisford et al. 2011). c Ectopic expression of slo-1 from the
pharyngeal muscle-specific promoter myo-2 fails to rescue the
disrupted pattern of pharyngeal activity (i.e. the bursting activity is
still observed) in line with earlier observations that this is a neuronally
derived phenotype; however, it does confer sensitivity of the pharynx
to emodepside. This is consistent with the suggestion that emodepside
can signal through SLO-1 when it is ectopically expressed in the
muscle to inhibit activity
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charged residues, two in the second transmembrane domain
(S2), one in the third transmembrane domain (S3) and one
in the fourth transmembrane domain (S4) (Ma et al. 2006).
Recently, it has been shown that there is a cooperative
interaction between S2 and S4 in terms of conferring
voltage sensitivity on the channel (Pantazis et al. 2010).
Thus, an interesting possibility is that emodepside may
exert its action within the membrane at the lipid–protein
interface between S2 and S4 to modulate voltage sensing.
There is a clear precedent for this kind of interaction pro-
vided by an analysis of the binding of a toxin from Chilean
Rode Tarantula to the potassium channel KvAP. This toxin
accesses the voltage sensor domain that lies within the
membrane (Lee and MacKinnon 2004). Indeed, there is a
growing appreciation that drug binding sites for ion chan-
nels may reside within the hydrophobic environment at the
lipid–protein interface.
The cytoplasmic domain of the BK channel provides the
calcium sensor which consists of a gating ring of two
domains per subunit, that is, eight in total in the functional
tetrameric channel, termed RCK for regulator of potassium
conductance. Structural studies have provided information
on the conformation of the closed gating ring (Wu et al.
2010) and the calcium-bound activated conformation
(Yuan et al. 2012). Intriguingly, a cluster of mutations that
confer resistance to emodepside were mapped to the RCK
domains, comprising the gating ring, of SLO-1 (Guest et al.
2007). This suggests significant determinants of efficacy
(and possible binding sites for emodepside) exist at the
protein–lipid interface of this domain. A speculative note is
that emodepside might interpose between the intracellular
gating ring and the pore domain to modulate channel
activity. Where ever the site of interaction of emodepside
within the SLO-1 channel might lie, defining it will have
important potential for understanding the molecular basis
of the mode of action of emodepside.
Summary
The means of targeting parasitic nematodes relies on a rel-
atively restricted pharmacological armoury of anthelmintics:
Fig. 3 A schematic of the structure of the SLO-1/BK calcium-
activated potassium channel. This is based on the information from
papers that have reported the structural properties of the human BK
channel (Latorre et al. 2010; Pantazis et al. 2010; Yuan et al. 2010,
2012) and a review of these data (Latorre et al. 2010). a A single a
subunit of the SLO-1 channel showing the relationship between the
voltage sensor domain, pore forming domain and calcium sensing
domain. S0 is the least conserved region between the different
isoforms of the channel, whereas the pore forming and calcium
sensing domains are highly conserved. The transmembrane segments
S2, S3 and S4 harbour charged residues as indicated which confer the
voltage sensitivity of the channel. b A simplified diagram (omitting
S0) showing the relationship between two a subunits of the SLO-1
tetramer and the opening of the channel
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The cyclo-octadepsipeptide emodepside provides a com-
pletely new pharmacological strategy that breaks resistance
acquired to other anthelmintic agents. SLO-1 is the most
significant player in its mode of action. Moreover, it
belongs to a family of channels that are highly conserved
through the animal phyla and implicated in a range of
therapeutic strategies and neurological disorders. Thus, not
only does understanding the mode of action of emodepside
provide a new anthelmintic strategy, it also has the
potential to provide a novel route for other pharmacother-
apies that require the capability to modulate neuronal or
muscle excitability (N’Gouemo 2011).
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